+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Psoriasis Drugs Market 2019-2025

  • PDF Icon


  • June 2020
  • Region: Global
  • Orion Market Research Private Limited
  • ID: 5129677
UP TO OFF until Dec 31st 2022
Global Psoriasis Drugs Market Size, Share & Trends Analysis Report by Drug Class (TNF Inhibitors, Interleukin Inhibitors, Vitamin D Analogs, and Others) by Route of Administration (Oral, Parenteral, and Topical), and Forecast 2019-2025.

The global psoriasis market is estimated to grow significantly during the forecast period. Psoriasis is a genetic condition and may be triggered by various environmental and genetic factors. It is not present by birth, rather it develops gradually. Sedentary lifestyles of people, unhealthy diet, excess consumption of alcohol, smoking, are some of the factors that lead and make peoples more prone to psoriasis. The primary factors that drive the growth of the market include increased incidences of psoriasis amongst the peoples. Rising awareness about the treatment and increased demand for enhanced healthcare infrastructure are some of the key growth factors of the market during the forecast period. Additionally, initiatives and awareness programs by government and private organizations are also supporting the growth of the market.

The global psoriasis market is segmented on the basis of drug class and route of administration. Based on the drug class, the market is segmented into TNF inhibitors, interleukin inhibitors, vitamin D analogs, and others. TNF inhibitors segment is estimated to hold a significant share in the market during the forecast period. Based on the route of administration, the market is segmented into oral, parenteral, and topical. Amongst the route of administration, the topical segment is likely to hold a significant share in the market.

AbbVie, Inc., Amgen Inc., Eli Lilly and Co., Johnson & Johnson Services Inc., Novartis International AG, AstraZeneca Plc, Boehringer Ingelheim International GmbH, Pfizer, Inc., and Sun Pharmaceutical Industries Ltd., are the prominent players functioning in the global Psoriasis Drugs market. New product launches & developments, partnerships, agreements, and acquisitions are some of the growth strategies adopted by the players to sustain in the highly competitive market. For instance, in March 2020, Eli Lilly and Co. received the FDA approval for a supplemental Biologics License Application for Taltz (ixekizumab) injection, 80 mg/mL for the treatment of pediatric patients (ages 6 to under 18) with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Research Methodology

The market study of the global psoriasis drugs market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The team collects facts and data related to the market from different geography to provide a better regional outlook.

In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. The analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity of the reports.

Secondary Sources Include:
  • Financial reports of companies involved in the market
  • Whitepapers, research-papers, and news blogs
  • Company websites and their product catalog
The report is intended for pharmaceutical companies, drug manufacturers, raw material suppliers, active pharmaceutical ingredient manufacturers, contract research organizations, contract manufacturers, industry associations & experts, research institutes, government organizations, regulatory bodies, and other market participants for overall market analysis and competitive analysis. The report provides an in-depth analysis of the market size and growth opportunities. The report will serve as a source for 360-degree analysis of the market thoroughly delivering insights into the market for making better business decisions.

Market Segmentation:

1. Global Psoriasis Drugs Market Research and Analysis by Drug Class
2. Global Psoriasis Drugs Market Research and Analysis by Route of Administration

The Report covers:
  • Comprehensive research methodology of the global Psoriasis Drugs market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global Psoriasis Drugs market.
  • Insights about market determinants which are stimulating the global Psoriasis Drugs market.
  • Detailed and extensive market segments with regional distribution of forecast revenues.
  • Extensive profiles and recent developments of the market players.

Table of Contents

1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations
3. Competitive Landscape
3.1. Key Strategy Analysis
3.2. Key Company Analysis
3.2.1. Amgen Inc. Overview Financial Analysis SWOT Analysis Recent Developments
3.2.2. Johnson & Johnson Services inc. Overview Financial Analysis SWOT Analysis Recent Developments
3.2.3. Abbvie Inc. Overview Financial Analysis SWOT Analysis Recent Developments
3.2.4. Eli Lilly & Co. Overview Financial Analysis SWOT Analysis Recent Developments
3.2.5. Novartis International AG Overview Financial Analysis SWOT Analysis Recent Developments
4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities
5. Market Segmentation
5.1. Global Psoriasis Drugs Market by Drug Class
5.1.1. Tumor Necrosis Factor (TNF) Inhibitors
5.1.2. Interleukin Inhibitors
5.1.3. Vitamin D Analogs
5.1.4. Others
5.2. Global Psoriasis Drugs Market by Route of Administration
5.2.1. Oral
5.2.2. Parenteral
5.2.3. Topical
6. Regional Analysis
6.1. North America
6.1.1. United States
6.1.2. Canada
6.2. Europe
6.2.1. UK
6.2.2. Germany
6.2.3. Italy
6.2.4. Spain
6.2.5. France
6.2.6. Rest of Europe
6.3. Asia-Pacific
6.3.1. China
6.3.2. India
6.3.3. Japan
6.3.4. Rest of Asia-Pacific
6.4. Rest of the World
7. Company Profiles
7.1. AbbVie, Inc.
7.2. Amgen Inc.
7.3. AstraZeneca Plc
7.4. Bausch Health Companies Inc.
7.5. Biogen, Inc.
7.6. Boehringer Ingelheim International GmbH
7.7. Celltrion Healthcare Co. Ltd.
7.8. Dr. Reddy's Laboratories Ltd.
7.9. Eli Lilly and Co.
7.10. Johnson & Johnson Services Inc.
7.11. LEO Pharma A/S
7.12. Merck & Co. Inc.
7.13. Novartis International AG
7.14. Pfizer, Inc.
7.15. Sun Pharmaceutical Industries Ltd.
7.16. Takeda Pharmaceutical Co. Ltd.
7.17. UCB SA

Companies Mentioned

A selection of companies mentioned in this report includes:

  • AbbVie, Inc.
  • Amgen Inc.
  • AstraZeneca Plc
  • Bausch Health Companies Inc.
  • Biogen, Inc.
  • Boehringer Ingelheim International GmbH
  • Celltrion Healthcare Co. Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Co.
  • Johnson & Johnson Services Inc.
  • LEO Pharma A/S
  • Merck & Co. Inc.
  • Novartis International AG
  • Pfizer, Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Co. Ltd.
  • UCB SA